Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARI-COG Study
2024-517768-52-00Phase 4Authorised
- Sponsor
- University of Rome Tor Vergata
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daridorexant in chronic insomnia, sponsored by University of Rome Tor Vergata. Primary endpoints: Change in Insomnia Severity Index (ISI) total score at 3 and 6 months and Change in subjective total sleep time (sTST). Planned start Mar 2025; status: authorised.
02
Drugs
daridorexant
03
Conditions
chronic insomnia
Beyond the preview
Go deeper on 2024-517768-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517768-52-00.